Philip Seeman: Difference between revisions
Content deleted Content added
Red Director (talk | contribs) m Changing short description from "Canadian pharmacologist" to "Canadian pharmacologist (1934–2021)" |
Also Parkinson's and Huntington's |
||
| (One intermediate revision by the same user not shown) | |||
| Line 19: | Line 19: | ||
==Career== |
==Career== |
||
Born in [[Winnipeg]], [[Manitoba]], Seeman was raised in [[Montreal]]. He received a [[Bachelor of Science]] degree, honours physics & physiology (1955), a [[Master of Science]] degree, physiology of transport & secretion (1956), and a [[Doctor of Medicine]] (1960) from [[McGill University]]. In 1966, he received a Ph.D. in life sciences from [[Rockefeller University]]. |
Born in [[Winnipeg]], [[Manitoba]], Seeman was raised in [[Montreal]]. He received a [[Bachelor of Science]] degree, honours physics & physiology (1955), a [[Master of Science]] degree, physiology of transport & secretion (1956), and a [[Doctor of Medicine]] (1960) from [[McGill University]]. In 1966, he received a Ph.D. in life sciences from [[Rockefeller University]] under the supervision of [[George Emil Palade]].<ref name=Peters>{{cite web |last1=Peters |first1=Diane |title=Researcher Philip Seeman shed new light on biology of schizophrenia |url=https://www.theglobeandmail.com/canada/article-researcher-philip-seeman-shed-new-light-on-biology-of-schizophrenia/ |website=The Globe and Mail |access-date=15 August 2024 |date=27 January 2021}}</ref> |
||
In 1967, Seeman became an assistant professor in the Department of Pharmacology at the [[University of Toronto]]. In 1970, he was appointed a professor. |
In 1967, Seeman became an assistant professor in the Department of Pharmacology at the [[University of Toronto]]. In 1970, he was appointed a professor. |
||
In 1974, having spent years in search of the binding site of antipsychotic medication, he discovered the [[Dopamine receptor|dopamine D2 receptor]], the basis for the [[dopamine hypothesis of schizophrenia]].<ref>{{Cite journal| author = P. Seeman, M. Chau-Wong, J. Tedesco & K. Wong| title = Brain receptors for antipsychotic drugs and dopamine: direct binding assays| journal = [[Proceedings of the National Academy of Sciences of the United States of America]]| volume = 72| issue = 11| pages = 4376–4370|date=November 1975| pmid = 1060115| pmc = 388724| doi = 10.1073/pnas.72.11.4376| bibcode = 1975PNAS...72.4376S| doi-access = free}}</ref><ref>{{cite journal|title=People|journal=CMAJ|year=1994|volume=151|number=8|pages= 1186–1187|pmc=1337253}}</ref> |
In 1974, having spent years in search of the binding site of antipsychotic medication, he discovered the [[Dopamine receptor|dopamine D2 receptor]], the basis for the [[dopamine hypothesis of schizophrenia]].<ref>{{Cite journal| author = P. Seeman, M. Chau-Wong, J. Tedesco & K. Wong| title = Brain receptors for antipsychotic drugs and dopamine: direct binding assays| journal = [[Proceedings of the National Academy of Sciences of the United States of America]]| volume = 72| issue = 11| pages = 4376–4370|date=November 1975| pmid = 1060115| pmc = 388724| doi = 10.1073/pnas.72.11.4376| bibcode = 1975PNAS...72.4376S| doi-access = free}}</ref><ref>{{cite journal|title=People|journal=CMAJ|year=1994|volume=151|number=8|pages= 1186–1187|pmc=1337253}}</ref> His discoveries also helped advance research on other diseases involving dopamine, such as [[Parkinson's disease]] and [[Huntington's disease]].<ref name=Peters/> |
||
In 2001, he was made an Officer of the [[Order of Canada]] "for his research on dopamine receptors and their involvement in diseases such as schizophrenia, Parkinson's and Huntington's".<ref>{{OCC|4875}}</ref> |
In 2001, he was made an Officer of the [[Order of Canada]] "for his research on dopamine receptors and their involvement in diseases such as schizophrenia, Parkinson's and Huntington's".<ref>{{OCC|4875}}</ref> |
||
Latest revision as of 18:53, 15 August 2024
 | This article is an autobiography or has been extensively edited by the subject or by someone connected to the subject. (February 2013) |
Philip Seeman | |
|---|---|
| Born | 8 February 1934 |
| Died | 9 January 2021 (aged 86) |
| Awards | Order of Canada |
Philip Seeman, OC FRSC (8 February 1934 – 9 January 2021) was a Canadian schizophrenia researcher and neuropharmacologist, known for his research on dopamine receptors.[1]
Career
[edit]Born in Winnipeg, Manitoba, Seeman was raised in Montreal. He received a Bachelor of Science degree, honours physics & physiology (1955), a Master of Science degree, physiology of transport & secretion (1956), and a Doctor of Medicine (1960) from McGill University. In 1966, he received a Ph.D. in life sciences from Rockefeller University under the supervision of George Emil Palade.[2]
In 1967, Seeman became an assistant professor in the Department of Pharmacology at the University of Toronto. In 1970, he was appointed a professor.
In 1974, having spent years in search of the binding site of antipsychotic medication, he discovered the dopamine D2 receptor, the basis for the dopamine hypothesis of schizophrenia.[3][4] His discoveries also helped advance research on other diseases involving dopamine, such as Parkinson's disease and Huntington's disease.[2]
In 2001, he was made an Officer of the Order of Canada "for his research on dopamine receptors and their involvement in diseases such as schizophrenia, Parkinson's and Huntington's".[5]
In 1985, he was made a Fellow of the Royal Society of Canada.[6]
He was married to Dr. Mary V. Seeman.[7]
Notes
[edit]- ^ "Philip SEEMAN". The Globe and Mail. Retrieved 19 January 2021.
- ^ a b Peters, Diane (27 January 2021). "Researcher Philip Seeman shed new light on biology of schizophrenia". The Globe and Mail. Retrieved 15 August 2024.
- ^ P. Seeman, M. Chau-Wong, J. Tedesco & K. Wong (November 1975). "Brain receptors for antipsychotic drugs and dopamine: direct binding assays". Proceedings of the National Academy of Sciences of the United States of America. 72 (11): 4376–4370. Bibcode:1975PNAS...72.4376S. doi:10.1073/pnas.72.11.4376. PMC 388724. PMID 1060115.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ "People". CMAJ. 151 (8): 1186–1187. 1994. PMC 1337253.
- ^ Order of Canada citation
- ^ "Science & Medicine - Science & Medicine". www.sciandmed.com. Archived from the original on 2011-07-16.
- ^ "Most Wikipedia profiles are about men – these women in Australia are hoping to change that". SBS News. Retrieved 27 July 2019.
References
[edit]- Madras, B.K. (2013). "History of the discovery of the antipsychotic dopamine D2 receptor: A basis for the dopamine hypothesis of schizophrenia". Journal of the History of the Neurosciences: Basic and Clinical Perspectives. 22 (1): 62–78. doi:10.1080/0964704x.2012.678199. PMID 23323533. S2CID 12002684.
- Seeman, P. (2011). "All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2High receptors". CNS Neuroscience & Therapeutics. 17 (2): 118–132. doi:10.1111/j.1755-5949.2010.00162.x. PMC 6493870. PMID 20560996.
- P. Seeman (2010). "Dopamine D2 Receptors as Treatment Targets in Schizophrenia. Clinical Schizophrenia & Related Psychoses April: 56-73.
- P. Seeman (2007), Scholarpedia, 2(10): 3634 doi.4249/scholarpedia.3634
- Seeman, P. (2006). "Targeting the dopamine D2 receptor in schizophrenia". Expert Opinion on Therapeutic Targets. 10 (4): 515–531. doi:10.1517/14728222.10.4.515. PMID 16848689. S2CID 30902536.
- Seeman, P.; Weinshenker, D.; Quirion, R.; Srivastava, L.; Bhardwaj, S.K.; Grandy, D.K.; Premont, R.; Sotnikova, T.; Boksa, P.; El-Ghundi, M.; O'Dowd, B.F.; George, S.R.; Perreault, M.L.; Mannisto, P.T.; Robinson, S.; Palmiter, R.D.; Tallerico, T. (2005). "Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis". Proceedings of the National Academy of Sciences USA. 102 (9): 3513–3518. Bibcode:2005PNAS..102.3513S. doi:10.1073/pnas.0409766102. PMC 548961. PMID 15716360.
- Seeman, P.; Chau-Wong, M.; Tedesco, J.; Wong, K. (1975). "Brain receptors for antipsychotic drugs and dopamine: Direct binding assays". Proceedings of the National Academy of Sciences, USA. 72 (11): 4376–4380. Bibcode:1975PNAS...72.4376S. doi:10.1073/pnas.72.11.4376. PMC 388724. PMID 1060115.
External links
[edit]- Home Page of Philip Seeman's Laboratory
- Probing the Biology of Psychosis, Schizophrenia, and Antipsychotics: An Expert Interview With Dr. Philip Seeman, MD, PhD – an interview on the Medscape website
- Schizophrenia – an essay by Philip Seeman, November 2001
| International | |
|---|---|
| National | |
